Kidney Transplant Rejection Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Kidney Transplant Rejection pipeline constitutes 6+ key companies continuously working towards developing 8+ Kidney Transplant Rejection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Kidney Transplant Rejection Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Kidney Transplant Rejection Market.

The Kidney Transplant Rejection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Kidney Transplant Rejection Pipeline Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Kidney Transplant Rejection treatment therapies with a considerable amount of success over the years.
• Kidney Transplant Rejection companies working in the treatment market are Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Sangamo TherapeuticsInc., Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc, and others, are developing therapies for the Kidney Transplant Rejection treatment
• Emerging Kidney Transplant Rejection therapies in the different phases of clinical trials are- VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others are expected to have a significant impact on the Kidney Transplant Rejection market in the coming years.
• In December 2025, Three months after reporting positive Phase 3 results for its kidney transplant therapy imlifidase, which could support a first-time U.S. approval, Hansa Biopharma encountered a setback in a late-stage study for a different indication. The Swedish biotech did not achieve its desired outcomes in advancing imlifidase for the treatment of anti-glomerular basement membrane (anti-GBM) disease. In the GOOD-IDES-02 trial, about 60% of patients treated with imlifidase followed by standard care were able to avoid dialysis at six months, falling short of expectations.
• In November 2025, Eledon Pharmaceuticals' lead candidate, tegoprubart, is advancing to late-stage clinical trials for the prevention of kidney transplant rejection despite not meeting its primary efficacy endpoint. In the Phase II BESTOW trial (NCT06126380), tegoprubart did not show a statistically significant improvement in estimated glomerular filtration rate (eGFR) compared with the standard immunosuppressant tacrolimus. After 12 months of treatment, patients receiving the anti-CD40 ligand-binding antibody recorded an eGFR of 69 mL/min/1.73 m2, while those treated with tacrolimus achieved 66 mL/min/1.73 m2 over the same period.
• MDR-101, a cellular treatment created using bone marrow and blood cells from a living kidney donor. The therapy's goal is to enable kidney transplant recipients who have a living kidney donor who matches their genetic profile or their HLA to stop taking all immunosuppressive (anti-rejection) medications while preserving long-term kidney function and life.
• In May 2024, Human Immunology Biosciences (HI-Bio) has announced positive results from its Phase II clinical trial of felzartamab for treating late antibody-mediated rejection (AMR) in kidney transplant recipients. This investigator-sponsored, double-blind, placebo-controlled study assessed the safety and tolerability of felzartamab in adults who developed late AMR at least six months after undergoing a kidney transplant.
• In July 2023, Verici Dx, a clinical diagnostics developer for organ transplants, has achieved successful validation results from its prospective, blinded clinical validation study for Clarava. Clarava is a pre-transplant prognostic test that evaluates a patient's immune response and assesses the risk of early kidney transplant rejection. The test leverages RNA sequencing and utilizes artificial intelligence to determine an RNA signature from gene expression.

Kidney Transplant Rejection Overview
Kidney transplant rejection is an allogeneic immune reaction that degrades the graft's function and causes graft destruction. Patients who do not take their medicine as directed or who have insufficient immunosuppression frequently experience it. Chronic active antibody-mediated rejection (ABMR) and chronic active T cell-mediated rejection (TCMR) are the two main subtypes of kidney transplant rejection.

Get a Free Sample PDF Report to know more about Kidney Transplant Rejection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Kidney Transplant Rejection Drugs Under Different Phases of Clinical Development Include:
• VEL-101: Veloxis Pharmaceuticals, Inc.
• Tegoprubart: Eledon Pharmaceuticals, Inc.
• TX200: Sangamo Therapeutics
• Dazodalibep: Horizon Therapeutics Plc
• Clazakizumab: CSL Behring
• MDR-101: Medeor Therapeutics, Inc

Kidney Transplant Rejection Route of Administration
Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Kidney Transplant Rejection Molecule Type
Kidney Transplant Rejection Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Kidney Transplant Rejection Pipeline Therapeutics Assessment
• Kidney Transplant Rejection Assessment by Product Type
• Kidney Transplant Rejection By Stage and Product Type
• Kidney Transplant Rejection Assessment by Route of Administration
• Kidney Transplant Rejection By Stage and Route of Administration
• Kidney Transplant Rejection Assessment by Molecule Type
• Kidney Transplant Rejection by Stage and Molecule Type

DelveInsight's Kidney Transplant Rejection Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Kidney Transplant Rejection product details are provided in the report. Download the Kidney Transplant Rejection pipeline report to learn more about the emerging Kidney Transplant Rejection therapies
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Kidney Transplant Rejection Therapeutics Market include:
Key companies developing therapies for Kidney Transplant Rejection are - Astellas Pharma Inc, Medeor Therapeutics Inc, Bristol-Myers Squibb Co, Junten Bio Co Ltd, OSE Immunotherapeutics, Sangamo Therapeutics Inc, Talaris Therapeutics Inc, Eledon Pharmaceuticals Inc, Hillhurst Biopharmaceuticals Inc, Alphamab Oncology, and others.

Kidney Transplant Rejection Pipeline Analysis:
The Kidney Transplant Rejection pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Kidney Transplant Rejection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Kidney Transplant Rejection Treatment.
• Kidney Transplant Rejection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Kidney Transplant Rejection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Kidney Transplant Rejection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Kidney Transplant Rejection drugs and therapies
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Kidney Transplant Rejection Pipeline Market Drivers
• Rising prevalence of chronic kidney diseases, increasing number of kidney transplants are some of the important factors that are fueling the Kidney Transplant Rejection Market.

Kidney Transplant Rejection Pipeline Market Barriers
• However, lack of donor and knowledge, long waiting time for transplantation and other factors are creating obstacles in the Kidney Transplant Rejection Market growth.

Scope of Kidney Transplant Rejection Pipeline Drug Insight
• Coverage: Global
• Key Kidney Transplant Rejection Companies: Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Sangamo TherapeuticsInc., Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc, and others
• Key Kidney Transplant Rejection Therapies: VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others
• Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies
• Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.